Literature DB >> 22461527

Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.

Elizabeth E Moran1, Robert Burden, Joseph E Labrie, Zhiyun Wen, Xin-Min Wang, Wendell D Zollinger, Lan Zhang, Valerian B Pinto.   

Abstract

Rabbit immunogenicity studies on an experimental trivalent native outer membrane vesicle vaccine derived from three serogroup B strains were conducted to evaluate the effectiveness of this vaccine at inducing an antibody response with serum bactericidal activity against meningococcal strains of other serogroups in addition to serogroup B strains. The results showed that the vaccine was capable of inducing an effective broad-based bactericidal antibody response in rabbits against a small sample of Neisseria meningitidis strains of serogroups C, W135, and X and, to a lesser extent, serogroups A and Y. Analysis of antibody specificity using a bactericidal depletion assay revealed that antibodies to lipooligosaccharide (LOS), PorA, and NadA induced in rabbits by the experimental trivalent outer membrane vesicle vaccine were responsible for most of the bactericidal activity against strains of the other N. meningitidis serogroups. In the case of serogroup A N. meningitidis strains, the outer membrane antigen NadA was primarily responsible for protection. The outer membrane antigens fHbp and OpcA were also effective in removing some bactericidal activity from the sera.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22461527      PMCID: PMC3346344          DOI: 10.1128/CVI.00070-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  30 in total

1.  Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger.

Authors:  Pascal Boisier; Pierre Nicolas; Saacou Djibo; Muhamed-Kheir Taha; Isabelle Jeanne; Halima Boubacar Maïnassara; Bernard Tenebray; Kiari Kaka Kairo; Dario Giorgini; Suzanne Chanteau
Journal:  Clin Infect Dis       Date:  2007-01-25       Impact factor: 9.079

2.  Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms.

Authors:  M C Maiden; J A Bygraves; E Feil; G Morelli; J E Russell; R Urwin; Q Zhang; J Zhou; K Zurth; D A Caugant; I M Feavers; M Achtman; B G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

3.  Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine.

Authors:  I Claassen; J Meylis; P van der Ley; C Peeters; H Brons; J Robert; D Borsboom; A van der Ark; I van Straaten; P Roholl; B Kuipers; J Poolman
Journal:  Vaccine       Date:  1996-07       Impact factor: 3.641

4.  Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors:  J Finne; M Leinonen; P H Mäkelä
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

5.  Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity.

Authors:  E E Moran; B L Brandt; W D Zollinger
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

6.  Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation.

Authors:  J Armand; F Arminjon; M C Mynard; C Lafaix
Journal:  J Biol Stand       Date:  1982-10

7.  An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups.

Authors:  Valerian B Pinto; Elizabeth E Moran; Francisco Cruz; Xin-Ming Wang; Arthur Fridman; Wendell D Zollinger; Craig T Przysiecki; Robert Burden
Journal:  Vaccine       Date:  2011-08-07       Impact factor: 3.641

8.  NadA, a novel vaccine candidate of Neisseria meningitidis.

Authors:  Maurizio Comanducci; Stefania Bambini; Brunella Brunelli; Jeannette Adu-Bobie; Beatrice Aricò; Barbara Capecchi; Marzia Monica Giuliani; Vega Masignani; Laura Santini; Silvana Savino; Dan M Granoff; Dominique A Caugant; Mariagrazia Pizza; Rino Rappuoli; Marirosa Mora
Journal:  J Exp Med       Date:  2002-06-03       Impact factor: 14.307

9.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870.

Authors:  Vega Masignani; Maurizio Comanducci; Marzia Monica Giuliani; Stefania Bambini; Jeannette Adu-Bobie; Beatrice Arico; Brunella Brunelli; Alessandro Pieri; Laura Santini; Silvana Savino; Davide Serruto; David Litt; Simon Kroll; Jo Anne Welsch; Dan M Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more
  8 in total

1.  Label-free quantitative mass spectrometry for analysis of protein antigens in a meningococcal group B outer membrane vesicle vaccine.

Authors:  Lawrence W Dick; John T Mehl; John W Loughney; Anna Mach; Richard R Rustandi; Sha Ha; Lan Zhang; Craig T Przysiecki; Lance Dieter; Van M Hoang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Antigenic Variation in Bacterial Pathogens.

Authors:  Guy H Palmer; Troy Bankhead; H Steven Seifert
Journal:  Microbiol Spectr       Date:  2016-02

Review 3.  Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.

Authors:  Johan Holst; Philipp Oster; Richard Arnold; Michael V Tatley; Lisbeth M Næss; Ingeborg S Aaberge; Yvonne Galloway; Anne McNicholas; Jane O'Hallahan; Einar Rosenqvist; Steven Black
Journal:  Hum Vaccin Immunother       Date:  2013-03-07       Impact factor: 3.452

Review 4.  Outer membrane vesicles as platform vaccine technology.

Authors:  Leo van der Pol; Michiel Stork; Peter van der Ley
Journal:  Biotechnol J       Date:  2015-09       Impact factor: 4.677

Review 5.  Progress Toward a Gonococcal Vaccine: The Way Forward.

Authors:  Michael W Russell; Ann E Jerse; Scott D Gray-Owen
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

6.  The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.

Authors:  Valerian B Pinto; Robert Burden; Allyn Wagner; Elizabeth E Moran; Che-Hung Lee
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

7.  Bioinformatic analysis of meningococcal Msf and Opc to inform vaccine antigen design.

Authors:  Clio A Andreae; Richard B Sessions; Mumtaz Virji; Darryl J Hill
Journal:  PLoS One       Date:  2018-03-16       Impact factor: 3.240

Review 8.  Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets.

Authors:  Arno Thibau; Alexander A Dichter; Diana J Vaca; Dirk Linke; Adrian Goldman; Volkhard A J Kempf
Journal:  Med Microbiol Immunol       Date:  2019-12-01       Impact factor: 3.402

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.